{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:40:12Z","timestamp":1759041612731,"version":"3.44.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a broad overview on the use of these agents in the first-line setting, incorporating a review of the clinical literature as well as the practice patterns of our respective melanoma groups. Throughout, we highlight areas of uncertainty that provide opportunities for future clinical investigation and additional improvement in outcomes for patients with melanoma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000704","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T16:01:18Z","timestamp":1711382478000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease"],"prefix":"10.1097","volume":"30","author":[{"given":"James W.","family":"Smithy","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul B.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250928","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s43018-022-00447-1","article-title":"Anti\u2013CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc\u03b3R engagement and type I interferon signaling","volume":"3","year":"2022","journal-title":"Nat Cancer"},{"key":"bib2-20250928","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib3-20250928","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"key":"bib4-20250928","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","year":"2019","journal-title":"Ann Oncol"},{"key":"bib5-20250928","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"bib6-20250928","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib7-20250928","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib8-20250928","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib9-20250928","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"bib10-20250928","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib11-20250928","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib12-20250928","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib13-20250928","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: results of the phase II study CheckMate 204","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib14-20250928","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib15-20250928","doi-asserted-by":"crossref","first-page":"CT013","DOI":"10.1158\/1538-7445.AM2022-CT013","article-title":"SWOG S1616: ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti\u2013PD-1 therapy","volume":"82","year":"2022","journal-title":"Cancer Res"},{"key":"bib16-20250928","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti\u2013PD-1\/L1 failure in melanoma","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib17-20250928","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib18-20250928","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.21.01570","article-title":"Adaptive dosing of nivolumab + ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (the ADAPT-IT study)","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib19-20250928","doi-asserted-by":"crossref","first-page":"9517","DOI":"10.1200\/JCO.2023.41.16_suppl.9517","article-title":"Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib20-20250928","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"bib21-20250928","first-page":"EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","journal-title":"NEJM Evid"},{"key":"bib22-20250928","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2023.41.16_suppl.9502","article-title":"Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib23-20250928","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","year":"2002","journal-title":"Nature"},{"key":"bib24-20250928","first-page":"6997","article-title":"BRAF and RAS mutations in human lung cancer and melanoma","volume":"62","year":"2002","journal-title":"Cancer Res"},{"key":"bib25-20250928","first-page":"5198","article-title":"Suppression of BRAF(V599E) in human melanoma abrogates transformation","volume":"63","year":"2003","journal-title":"Cancer Res"},{"key":"bib26-20250928","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","year":"2003","journal-title":"Nat Genet"},{"key":"bib27-20250928","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","year":"2010","journal-title":"N Engl J Med"},{"key":"bib28-20250928","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013mutant advanced melanoma treated with vemurafenib","volume":"366","year":"2012","journal-title":"N Engl J Med"},{"key":"bib29-20250928","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"bib30-20250928","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib31-20250928","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","year":"2015","journal-title":"N Engl J Med"},{"key":"bib32-20250928","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib33-20250928","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"bib34-20250928","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib35-20250928","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.21.01601","article-title":"Randomized phase III trial evaluating spartalizumab plus dabrafenib and trametinib for BRAF V600\u2013mutant unresectable or metastatic melanoma","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib36-20250928","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib37-20250928","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"bib38-20250928","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1200\/JCO.21.02801","article-title":"PD-1 or PD-L1 blockade adds little to combination of BRAF and MEK inhibition in the treatment of BRAF V600\u2013mutated melanoma","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib39-20250928","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib40-20250928","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"bib41-20250928","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","year":"2022","journal-title":"Nature"},{"key":"bib42-20250928","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib43-20250928","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib44-20250928","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"bib45-20250928","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","year":"2022","journal-title":"Nat Med"},{"key":"bib46-20250928","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/JCO.2023.41.16_suppl.101","article-title":"The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: three-year data of PRADO and OpACIN-neo","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib47-20250928","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib48-20250928","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"Adjuvant pembrolizumab in resected stage III melanoma","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib49-20250928","first-page":"EVIDoa2200214","article-title":"Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma","volume":"1","year":"2022","journal-title":"NEJM Evid"},{"key":"bib50-20250928","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","year":"2017","journal-title":"N Engl J Med"},{"key":"bib51-20250928","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"bib52-20250928","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1200\/JCO.2023.41.16_suppl.9518","article-title":"Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma","volume":"41","year":"2023","journal-title":"J Clin Oncol"},{"key":"bib53-20250928","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/oncolo\/oyac266","article-title":"Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy","volume":"28","year":"2023","journal-title":"Oncologist"},{"key":"bib54-20250928","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"bib55-20250928","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","year":"2023","journal-title":"Nat Med"},{"key":"bib56-20250928","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","year":"2023","journal-title":"N Engl J Med"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:00:46Z","timestamp":1759039246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000704","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"type":"electronic","value":"1540-336X"},{"type":"print","value":"1528-9117"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}